Three Hengxu Capital-Backed Companies Recognized in KPMG China's Third Biotech Innovation Leading 50 List and File IPO Prospectuses

Apr 30, 2025 17:30 CST Updated 17:30

KAI MEDTECH

Neurointerventional Medical Device R&D and Manufacturer

Ribo Life Science

Small Nucleic Acid Drug Developer

【Hengxu Partner】

Three Portfolio Companies of Hengxu Capital

AwardedKPMG China's 3rd Biotech Innovation Pioneer 50 List

2025/04/30

April 28,KPMG China, in collaboration with the Hainan International Pharmaceutical Innovation Foundation and Suzhou Biobay, successfully hosted"KPMG China's 3rd Bio-Innovation Leader 50 Enterprise List Release and Award Ceremony"。Portfolio Companies of Hengxu CapitalBRATTEA, KAI MEDTECH, and Ribo Life Science have successfully made the list.

This year's selection, branded as the "China Biotech Innovation Leadership List" with a refreshed and upgraded approach, builds on the forward-looking insights of the previous two editions. By fully leveraging the advantages of industrial clusters and policy resources, it further supports the biotechnology sector in building a globally competitive highland for pharmaceuticals and health industry development, continuously empowering high-quality growth in the biopharmaceutical industry. The list evaluates companies based on six key dimensions: leadership in technology and product pipelines, diversity and proportion of proprietary products, background of core management and R&D teams, industrialization prospects, capital market activity, and financial health. It highlights leading enterprises across various subfields, including biopharmaceuticals, cell and gene therapy, in vitro diagnostics, medical devices, pharmaceutical outsourcing, AI-driven drug discovery, and innovative traditional Chinese medicine.

In the future, driven by multiple factors such as policy, technology, and ecosystem, Chinese biotechnology companies are expected to integrate into the global innovation chain with a more open attitude. Relying on continuously accumulated technical advantages, extensive research and development experience, and vast market space, they will stand out in global biotechnology competition.

The three invested companies selected by Hengxu this time are excellent cases of Hengxu Capital's investments in the biopharmaceutical and health consumption sectors in recent years.

Overview of the Award-Winning Company:

BRATTEA

BRATTEA, founded in 2013, focuses on the field of minimally invasive interventional treatment. Its core product, the Netrod Renal Artery Radiofrequency Ablation System, has been approved by the NMPA for marketing and is used for the treatment of resistant hypertension. Its technology platform covers various energy forms such as radiofrequency, ultrasound, and pulsed electric fields. The products have obtained CE certification and FDA Breakthrough Device Designation and completed the first overseas surgery, demonstrating global potential. With the vision of "solving chronic disease treatment pain points with minimally invasive technology," the company continues to expand innovative therapies in areas such as diabetes and heart failure.

KAI MEDTECH

KAI MEDTECH, founded in 2019, focuses on the research and development and production of neurointerventional medical devices, with products covering the entire pipeline of hemorrhagic, ischemic, and access categories. The company adopts a "self-developed + global technology acquisition" dual-driven approach to quickly roll out multiple innovative products, such as the Skathi distal access catheter and Cyllene aneurysm-assisting stent. With solid technical accumulation and international layout, KAI MEDTECH has shown excellent performance in centralized procurement, achieving leapfrog growth in sales revenue, and plans to further consolidate its production capacity through a new manufacturing base.

Ribo Life Science

Ribo Life Science was founded in 2007,Is a leading company in China's small nucleic acid drug field,Focused on the development of RNA interference technology. Six self-developed siRNA drugs from Ribo Life Science are in clinical trial stages, with core products RBD4059 (anti-thrombotic) and RBD5044 (lipid-lowering) highlighted as the "world's first" and "best potential," respectively. Leveraging an efficient R&D system, Ribo Life Science has achieved the process from target discovery to clinical submission in just 20 months. Recently, the company submitted an IPO application to the Hong Kong Stock Exchange, accelerating the international expansion of its pipeline for chronic diseases such as cardiovascular, metabolic, and liver diseases.

About Hengxu Capital

Hengxu Capital (AMAC Registration No.: P1070270) was established in 2019. As a private equity investment institution under SAIC Motor Corporation Limited (referred to as "SAIC Motor," 600104.SH) financial platform, Shanghai Automotive Group Financial Control Management Co., Ltd. (referred to as "SAIC FCMC"), Hengxu Capital relies on the overall industrial advantages of SAIC Motor and the efficient collaborative empowerment of SAIC FCMC to contribute to the development of SAIC Motor's innovation industry chain and the improvement of its mobility ecosystem.Hengxu Capital's equity investment sector is committed to laying out strategic emerging industries such as green transportation, mobility ecosystems, and health ecosystems, while its alternative investment sector focuses on high-quality assets in the photovoltaic and energy storage fields.The company's vision is to enable investors to achieve good returns while promoting the coordinated development of Environment, Social, and Governance ("ESG"), and to become a respected outstanding industrial capital and a trusted first-class investment institution.

Hengxu Capital has accumulated a management scale exceeding 40 billion yuan, with investors including industry leaders, financial institutions, national governments, and market organizations. The core team possesses abundant industry resources and extensive experience in project management and fund management. They have led investments in dozens of high-quality enterprises such as CATL, Horizon Robotics, Jien Hydrogen Technology, Tongxingbao, Qingtao Energy, ChipON Microelectronics, Ascentage Pharma, and Skypaws Pets, accompanying these companies to grow into leading enterprises in their respective niche markets.